Rzeszow

• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• A Phase 2, Double-Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of EE and Maintenance of Healed EE in Pediatric … Ended
  2022-501350-11-00 4 2026-04-09 Erosive Esophagitis
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• Testing Insulin Enemas for Ulcerative Colitis: A First-Stage Clinical Trial Ended
  2023-510335-11-00 3 2025-02-04 Ulcerative colitis
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended
  2023-510341-19-00 5 2024-11-14 acne vulgaris
• A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB … Ended
  2023-507376-50-00 1 2024-09-27 Ulcerative Colitis
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete … Ended
  2022-502677-42-00 5 2024-07-24 Type 2 diabetes
• A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended
  2024-511331-96-00 4 2024-07-04 Mixed Dyslipidemia
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended
  2023-507410-27-00 4 2024-06-19 Severe Asthma
• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended
  2023-503522-40-01 4 2024-04-10 Atopic Dermatitis
• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub … Ended
  2023-508013-16-00 5 2024-02-26 Birch pollen induced allergic rhinitis or rhinoconjunctivitis
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended
  2022-502997-18-00 3 2024-02-02 Atopic Dermatitis
• A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and … Ended
  2023-503577-38-00 1 2023-12-07 Atopic Dermatitis

Showing 241–264 of 329 trials